Furthermore, treatment of ADPKD transplant-recipient patients with mTOR inhibitor was associated with significant reduction of the size of the endogenous polycystic kidney, indicating the key role of mTOR in ADPKD pathology [44]. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.